Arndt Vogel

Arndt Vogel: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared an article by Daniel H. Palmer, et al. on X:

“Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.

Supports GemCap for R0 & lymph node-negative patients not eligible for mFOLFIRINOX.”

Arndt Vogel: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.

Authors: Daniel H. Palmer, et al.

Arndt Vogel: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Adjuvant Therapy Arndt Vogel cancer Daniel H. Palmer π„π§ππ¨πœπ«π’π§π¨π₯𝐨𝐠𝐲 ESPAC4 fight against cancer Gastroenterology Global fight against cancer Hannover Medical School Hepatology mFOLFIRINOX OncoDaily Oncology pancreatic adenocarcinoma